

Supplementary Information

Catalytic asymmetric inverse-electron-demand aza-Diels–Alder reaction of 1,3-diazadienes with 3-vinylindoles

Yu-Hang Miao, Yuan-Zhao Hua,* Hao-Jie Gao, Nan-Nan Mo, Min-Can Wang,* and Guang-Jian Mei*

Green Catalysis Center, and College of Chemistry, Zhengzhou University, Zhengzhou 450001,
China.

E-mail: hyzh@gs.zzu.edu.cn; wangmincan@zzu.edu.cn; meigj@zzu.edu.cn.


Contents

1. General Information.....	2
2. General Procedures for the Synthesis of Isothiourea 3.....	3
3. Synthesis of Isothiourea 4.....	4
4. Characterization of benzothiazolopyrimidines.....	5
5. Crystallographic data collection for compound 3oa.....	23
6. HPLC spectra of compounds.....	25
7. NMR Spectra of compounds.....	70

1. General Information.


All reactions were carried out in oven-dried glassware with magnetic stirring. Reagents were obtained from commercial supplier and used without further purification unless otherwise noted. Solvents were dried with standard methods and freshly distilled prior to use if needed. All reactions sensitive to air or moisture were carried out under nitrogen using standard Schlenk and vacuum line techniques. NMR spectra were recorded on a 400 MHz NMR spectrometer with d_6 -DMSO as the solvent and TMS as an internal standard (400 MHz for ^1H and 100 MHz for ^{13}C). HRMS were determined on a Q-TOF Micro LC/MS System ESI spectrometer. Enantiomeric excesses values were determined with HPLC (chiral column; mobile phase hexane/*i*-PrOH).

2. General Procedures for the Synthesis of Isothiourea **3**.



To a solution of imine **1** (1 equiv) and catalyst CPA-5 (10 mol%) in dry DCM (1 mL), was added the 3-vinylindole **2** (1 equiv) in one portion. The reaction mixture was stirred for 12 h at rt. After completion (monitored by TLC), the solvent was removed under reduced pressure and the crude product was directly purified by flash chromatography on silica gel employing mixtures of DCM and ethyl acetate as eluents to afford the desired product **3**.

3. Synthesis of Isothiourea 4.




To a solution of imine **1c** (1.5 mol) and catalyst CPA-5 (10 mol%) in dry DCM (0.1 M), was added the 3-vinylindole **2a** (1 equiv) in one portion. The reaction mixture was stirred for 24 h at rt. After completion (monitored by TLC), the solvent was removed under reduced pressure and the crude product was directly purified by flash chromatography on silica gel employing mixtures of DCM and ethyl acetate as eluents to afford the desired product **3ca**.

To a solution of **3ca** (0.1 mmol) in dry THF (0.1 M) at 0 °C was added NaH (0.12 mmol, 1.2 equiv). Reaction was stirred for 30 min. Then, add of CH₃I (0.12 mol, 1.2 equiv). The solution was stirred at rt for the necessary reaction time, and then quenched with aqueous NH₄Cl (5 mL), and extracted three times with ethyl acetate (3×5 mL). The combined organics was washed with brine before being dried by MgSO₄, filtered and concentrated in vacuo. The crude product was separated by flash column chromatography on silica gel (petroleum ether/ethyl acetate 5:1–2:1) to afford a compound **4** as a white solid.


4. Characterization of benzothiazolopyrimidines.

(2*R*,3*S*,4*S*)-4-(1*H*-indol-3-yl)-2,3-diphenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3aa**:




White solid, M.p.: 161-162 °C; yield: 65%; $[\alpha]_D^{20} = +26$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), *t*₁ = 18.75 min (major), *t*₂ = 21.58 min (minor), ee = 96%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.81 (s, 1H), 7.46-7.42 (m, 1H), 7.38-7.30 (m, 1H), 7.25-7.19 (m, 1H), 7.12-6.98 (m, 9H), 6.96-6.61 (m, 6H), 6.56 (d, *J* = 7.3 Hz, 1H), 5.70 (d, *J* = 10.0 Hz, 1H), 4.84 (d, *J* = 10.3 Hz, 1H), 3.22 (t, *J* = 10.2 Hz, 1H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 157.8, 143.9, 140.5, 136.8, 129.2, 128.3, 128.1, 127.9, 126.8, 126.7, 125.7, 125.5, 125.0, 122.2, 122.1, 121.8, 121.5, 119.5, 118.2, 112.4, 112.0, 111.5, 64.7, 58.0, 53.6; HRMS (ESI) Calcd. For C₃₀H₂₄N₃S [M+H]⁺ 458.1685, found 458.1688.

(2*R*,3*S*,4*S*)-2-(4-fluorophenyl)-4-(1*H*-indol-3-yl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3ba**:




White solid, M.p.: 182-183 °C; yield: 74%; $[\alpha]_D^{20} = +121$ (*c* 0.23, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 8/92, flow rate 1.0 mL/min, $\lambda = 254$ nm), *t*₁ = 33.64 min (minor), *t*₂ = 36.96 min (major), ee = >99%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.82 (s, 1H), 7.44-7.41 (m, 1H), 7.30 (d, *J* = 7.8 Hz, 1H), 7.24 (d, *J* = 8.0 Hz, 1H), 7.06-6.95 (m, 7H), 6.91-6.77 (m, 7H), 6.55 (d, *J* = 7.2 Hz, 1H), 5.71 (d, *J* = 10.0 Hz, 1H), 4.85 (d, *J* = 10.2 Hz, 1H), 3.18 (t, *J* = 10.1 Hz, 1H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 161.1 (d, *J* = 240.2 Hz), 157.9, 140.5, 140.4, 140.1 (d, *J* = 2.8 Hz), 136.8, 129.8 (d, *J* = 8.0 Hz), 129.2, 128.4, 126.9, 125.8, 125.5, 125.0, 122.2, 122.2, 121.8, 121.5, 119.5, 118.2, 114.6 (d, *J* = 21.0 Hz) 112.4, 112.1, 111.4, 63.9, 57.9, 53.8; ¹⁹F NMR (376 MHz, d₆-DMSO) δ ppm: -111.98; HRMS (ESI) Calcd. For C₃₀H₂₃FN₃S [M+H]⁺ 476.1591, found 476.1595.

(2*R*,3*S*,4*S*)-2-(4-chlorophenyl)-4-(1*H*-indol-3-yl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3ca**:




White solid, M.p.: 154-155 °C; yield: 76%; $[\alpha]_D^{20} = +119$ (*c* 0.28, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 26.81$ min (minor), $t_2 = 29.00$ min (major), ee = >99%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.83 (s, 1H), 7.44-7.41 (m, 1H), 7.37-7.24 (m, 2H), 7.19-7.07 (m, 2H), 7.05-6.96 (m, 7H), 6.92-6.78 (m, 5H), 6.56 (d, *J* = 7.4 Hz, 1H), 5.71 (d, *J* = 10.0 Hz, 1H), 4.86 (d, *J* = 10.2 Hz, 1H), 3.18 (t, *J* = 10.2 Hz, 1H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 158.1, 142.9, 140.5, 140.2, 136.8, 131.1, 129.9, 129.2, 128.4, 127.9, 127.0, 125.8, 125.6, 125.0, 122.2, 121.9, 121.5, 119.6, 118.2, 112.4, 112.1, 111.3, 63.9, 57.9, 53.6; HRMS (ESI) Calcd. For C₃₀H₂₃ClN₃S [M+H]⁺ 492.1296, found 492.1299.

(2*R*,3*S*,4*S*)-2-(4-bromophenyl)-4-(1*H*-indol-3-yl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3da**:



White solid, M.p.: 182-183 °C; yield: 70%; $[\alpha]_D^{20} = +126$ (*c* 0.18, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 28.64$ min (minor), $t_2 = 32.26$ min (major), ee = 99%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.82 (s, 1H), 7.44-7.42 (m, 1H), 7.30-7.23 (m, 4H), 7.07-7.02 (m, 3H), 6.99-6.95 (m, 4H), 6.91-6.76 (m, 5H), 6.55 (d, *J* = 7.3 Hz, 1H), 5.70 (d, *J* = 10.0 Hz, 1H), 4.85 (d, *J* = 10.3 Hz, 1H), 3.17 (t, *J* = 10.1 Hz, 1H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 158.1, 143.4, 140.5, 140.3, 136.8, 130.8, 130.3, 129.2, 128.4, 127.0, 125.8, 125.0, 122.2, 122.2, 121.9, 121.5, 119.7, 119.5, 118.2, 112.4, 112.1, 111.3, 64.0, 57.9, 53.5; HRMS (ESI) Calcd. For C₃₀H₂₃BrN₃S [M+H]⁺ 536.0791, found 536.0795.


(2*R*,3*S*,4*S*)-4-(1*H*-indol-3-yl)-3-phenyl-2-(*p*-tolyl)-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3ea**:



White solid, M.p.: 167-168 °C; yield: 60%; $[\alpha]_D^{20} = +60$ (*c* 0.36, CH₂Cl₂); HPLC (Chiralpak IE, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 12.00$ min (minor), $t_2 = 13.02$ min (major), ee = 98%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.83 (s, 1H), 7.43-7.41 (m, 1H), 7.32-7.24 (m, 2H), 7.03-6.88 (m, 10H), 6.82-6.77 (m, 4H), 6.55 (d, *J* = 7.0 Hz, 1H), 5.66 (d, *J* = 10.1 Hz, 1H), 4.80 (d, *J* = 10.4 Hz, 1H), 3.20


(t, $J = 10.2$ Hz, 1H), 2.15 (s, 3H); ^{13}C NMR (100 MHz, $\text{d}_6\text{-DMSO}$) δ ppm: 157.7, 140.9, 140.6, 140.5, 136.8, 135.5, 129.3, 128.0, 126.8, 125.9, 125.7, 125.5, 125.0, 122.3, 122.1, 121.8, 121.5, 121.3, 119.5, 118.2, 112.4, 112.1, 111.5, 64.3, 58.1, 53.6, 21.1; HRMS (ESI) Calcd. For $\text{C}_{31}\text{H}_{26}\text{N}_3\text{S}$ $[\text{M}+\text{H}]^+$ 472.1842, found 472.1845.

(2*R*,3*S*,4*S*)-4-(1*H*-indol-3-yl)-2-(4-methoxyphenyl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3fa**:




White solid, M.p.: 261-262 °C; yield: 55%; $[\alpha]_D^{20} = +55$ (c 0.34, CH_2Cl_2); HPLC (Chiralpak ID, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 12.50$ min (minor), $t_2 = 17.62$ min (major), ee = 99%; ^1H NMR (400 M, $\text{d}_6\text{-DMSO}$) δ ppm: 10.66 (s, 1H), 7.47-7.42 (m, 1H), 7.23-7.14 (m, 3H), 7.10-7.01 (m, 6H), 6.88-6.78 (m, 6H), 6.61-6.59 (m, 2H), 5.67 (d, $J = 10.0$ Hz, 1H), 4.87 (d, $J = 10.3$ Hz, 1H), 3.71 (s, 3H), 3.19 (t, $J = 10.1$ Hz, 1H); ^{13}C NMR (100 MHz, $\text{d}_6\text{-DMSO}$) δ ppm: 158.3, 156.0, 143.1, 140.7, 140.4, 137.8, 131.3, 130.0, 129.4, 128.6, 128.0, 127.1, 125.7, 124.5, 122.4, 122.3, 122.1, 119.4, 118.9, 112.3, 111.5, 109.9, 95.6, 64.1, 58.2, 55.6, 53.9; HRMS (ESI) Calcd. For $\text{C}_{31}\text{H}_{26}\text{N}_3\text{OS}$ $[\text{M}+\text{H}]^+$ 488.1791, found 488.1789.

(2*R*,3*S*,4*S*)-4-(1*H*-indol-3-yl)-3-phenyl-2-(*m*-tolyl)-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3ga**:




White solid, M.p.: 137-138 °C; yield: 52%; $[\alpha]_D^{20} = +58$ (c 0.23, CH_2Cl_2); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 18.74$ min (minor), $t_2 = 21.28$ min (major), ee = 98%; ^1H NMR (400 M, $\text{d}_6\text{-DMSO}$) δ ppm: 10.85 (s, 1H), 7.46-7.43 (m, 1H), 7.34-7.26 (m, 2H), 7.15-7.01 (m, 7H), 7.00-6.81 (m, 6H), 6.80-6.74 (m, 2H), 6.59 (d, $J = 7.2$ Hz, 1H), 5.70 (d, $J = 10.0$ Hz, 1H), 4.82 (d, $J = 10.2$ Hz, 1H), 3.15 (t, $J = 10.1$ Hz, 1H), 2.11 (s, 3H); ^{13}C NMR (100 MHz, $\text{d}_6\text{-DMSO}$) δ ppm: 157.7, 143.7, 140.6, 140.5, 136.8, 129.2, 128.6, 128.3, 127.7, 127.3, 126.8, 125.9, 125.7, 125.5, 125.3, 125.0, 122.2, 122.1, 121.8, 121.5, 121.3, 119.5, 118.2, 112.4, 112.0, 111.5, 64.6, 58.0, 53.4, 21.4; HRMS (ESI) Calcd. For $\text{C}_{31}\text{H}_{26}\text{N}_3\text{S}$ $[\text{M}+\text{H}]^+$ 472.1842, found 472.1843.

(2*R*,3*S*,4*S*)-2-(3-chlorophenyl)-4-(1*H*-indol-3-yl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3ha**:




White solid, M.p.: 152-153 °C; yield: 72%; $[\alpha]_D^{20} = +58$ (*c* 0.23, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 23.34$ min (major), $t_2 = 27.44$ min (minor), ee = >99%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.89 (s, 1H), 7.51-7.43 (m, 1H), 7.38-7.23 (m, 4H), 7.18-6.98 (m, 7H), 6.93-6.78 (m, 5H), 6.54 (d, *J* = 6.7 Hz, 1H), 5.69 (d, *J* = 10.1 Hz, 1H), 4.87 (d, *J* = 10.3 Hz, 1H), 3.20 (t, *J* = 10.2 Hz, 1H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 158.3, 146.4, 140.5, 140.2, 136.8, 132.7, 129.7, 129.2, 128.5, 127.9, 127.0, 126.8, 126.7, 125.7, 125.6, 125.1, 122.2, 122.2, 121.9, 121.5, 119.6, 118.2, 112.4, 112.1, 111.4, 64.2, 57.9, 53.5; HRMS (ESI) Calcd. For C₃₀H₂₃ClN₃S [M+H]⁺ 492.1296, found 492.1299.

(2*R*,3*S*,4*S*)-4-(1*H*-indol-3-yl)-3-phenyl-2-(*o*-tolyl)-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3ia**:



White solid, M.p.: 178-179 °C; yield: 62%; $[\alpha]_D^{20} = +20$ (*c* 0.12, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 20.25$ min (major), $t_2 = 27.04$ min (minor), ee = 94%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.86 (s, 1H), 7.85-7.67 (m, 1H), 7.53-7.43 (m, 1H), 7.38-7.21 (m, 3H), 7.20-7.04 (m, 2H), 7.02-6.72 (m, 9H), 6.64-6.62 (m, 2H), 5.66 (d, *J* = 10.2 Hz, 1H), 4.86 (d, *J* = 10.4 Hz, 1H), 3.53 (t, *J* = 10.4 Hz, 1H), 0.95 (s, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 158.2, 142.9, 140.5, 139.2, 137.5, 136.8, 131.3, 129.9, 129.7, 128.1, 127.8, 126.7, 125.6, 125.3, 122.3, 122.3, 122.0, 121.7, 119.7, 118.0, 112.5, 112.3, 111.1, 64.2, 58.5, 47.8, 19.0; HRMS (ESI) Calcd. For C₃₁H₂₆N₃S [M+H]⁺ 472.1842, found 472.1845.


(2*R*,3*S*,4*S*)-2-(2-chlorophenyl)-4-(1*H*-indol-3-yl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3ja**:



White solid, M.p.: 182-183 °C; yield: 72%; $[\alpha]_D^{20} = +20$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 19.45$ min (major), $t_2 = 26.79$ min (minor), ee = >99%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.83 (s, 1H), 7.45-7.39 (m, 1H), 7.35-7.24 (m, 2H), 7.14-7.04 (m, 7H), 7.02-6.96 (m, 2H), 6.92-6.78 (m, 5H), 6.56 (d, *J* = 7.4 Hz, 1H), 5.72 (d, *J* = 10.0 Hz, 1H), 4.87 (d, *J*


= 10.3 Hz, 1H), 3.19 (t, J = 10.1 Hz, 1H); ^{13}C NMR (100 MHz, $\text{d}_6\text{-DMSO}$) δ ppm: 158.2, 143.0, 140.5, 140.3, 136.9, 131.2, 129.9, 129.3, 128.5, 127.9, 127.0, 125.8, 125.6, 125.0, 122.3, 122.2, 121.9, 121.6, 119.6, 118.2, 112.5, 112.1, 111.4, 64.0, 58.0, 53.6; HRMS (ESI) Calcd. For $\text{C}_{30}\text{H}_{23}\text{ClN}_3\text{S}$ $[\text{M}+\text{H}]^+$ 492.1296, found 492.1301.

(2*R*,3*S*,4*S*)-2-(2-bromophenyl)-4-(1*H*-indol-3-yl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3ka**:




White solid, M.p.: 186-187 °C; yield: 70%; $[\alpha]_{\text{D}}^{20}$ = +116 (c 0.24, CH_2Cl_2); HPLC (Chiralpak ID, *i*-propanol/hexane = 15/85, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 12.10 min (major), t_2 = 16.53 min (minor), ee = 98%; ^1H NMR (400 M, $\text{d}_6\text{-DMSO}$) δ ppm: 10.83 (s, 1H), 7.46-7.37 (m, 3H), 7.34-7.11 (m, 3H), 7.05-6.82 (m, 11H), 6.80-6.59 (m, 1H), 5.82 (d, J = 7.4 Hz, 1H), 5.28 (d, J = 4.6 Hz, 1H), 3.54 (s, 1H); ^{13}C NMR (100 MHz, $\text{d}_6\text{-DMSO}$) δ ppm: 158.1, 142.5, 140.5, 139.8, 136.8, 132.2, 130.3, 129.2, 128.9, 128.3, 127.8, 127.0, 125.6, 125.0, 123.6, 122.2, 122.2, 121.9, 121.5, 119.5, 118.3, 112.3, 111.9, 111.5, 63.1, 57.5, 51.9; HRMS (ESI) Calcd. For $\text{C}_{30}\text{H}_{23}\text{BrN}_3\text{S}$ $[\text{M}+\text{H}]^+$ 536.0791, found 536.0794.

(2*R*,3*S*,4*S*)-2-(benzo[*d*][1,3]dioxol-5-yl)-4-(1*H*-indol-3-yl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3la**:




White solid, M.p.: 204-205 °C; yield: 70%; $[\alpha]_{\text{D}}^{20}$ = +98 (c 0.32, CH_2Cl_2); HPLC (Chiralpak ID, *i*-propanol/hexane = 8/92, flow rate 1.0 mL/min, λ = 254 nm), t_1 = 15.43 min (minor), t_2 = 17.06 min (major), ee = >99%; ^1H NMR (400 M, $\text{d}_6\text{-DMSO}$) δ ppm: 10.81 (s, 1H), 7.45-7.39 (m, 1H), 7.35-7.21 (m, 2H), 7.08-6.95 (m, 5H), 6.92-6.76 (m, 5H), 6.61-6.46 (m, 4H), 5.86 (s, 2H), 5.66 (d, J = 10.0 Hz, 1H), 4.77 (d, J = 10.3 Hz, 1H), 3.19 (t, J = 10.2 Hz, 1H); ^{13}C NMR (100 MHz, $\text{d}_6\text{-DMSO}$) δ ppm: 157.6, 147.0, 145.8, 140.6, 140.5, 138.0, 136.8, 129.2, 128.3, 126.8, 125.7, 125.5, 125.0, 122.2, 122.1, 121.8, 121.5, 121.3, 119.5, 118.3, 112.4, 112.0, 111.5, 108.3, 107.7, 101.0, 64.3, 58.0, 53.6; HRMS (ESI) Calcd. For $\text{C}_{31}\text{H}_{24}\text{N}_3\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$ 502.1584, found 502.1585.

(2*R*,3*S*,4*S*)-4-(1*H*-indol-3-yl)-2-(naphthalen-1-yl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3ma**:




White solid, M.p.: 215-216 °C; yield: 68%; $[\alpha]_D^{20} = +100$ (*c* 0.31, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 15/85, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 20.43$ min (major), $t_2 = 23.18$ min (minor), ee = 99%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.86 (s, 1H), 7.57-7.21 (m, 4H), 7.17-7.00 (m, 11H), 6.97-6.79 (m, 5H), 6.61 (d, *J* = 7.3 Hz, 1H), 5.73 (d, *J* = 10.0 Hz, 1H), 4.89 (d, *J* = 10.3 Hz, 1H), 3.27 (t, *J* = 10.2 Hz, 1H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 158.9, 143.8, 142.3, 141.1, 137.5, 132.4, 132.0, 131.2, 130.6, 130.6, 129.2, 128.7, 126.5, 126.3, 125.7, 122.9, 122.9, 122.6, 122.5, 122.3, 120.3, 118.8, 113.1, 112.8, 111.7, 64.5, 58.2, 54.1; HRMS (ESI) Calcd. For C₃₄H₂₆N₃S [M+H]⁺ 508.1842, found 508.1841.

(2*R*,3*R*,4*S*)-4-(1*H*-indol-3-yl)-3-phenyl-2-(thiophen-2-yl)-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3ma**:



White solid, M.p.: 144-145 °C; yield: 70%; $[\alpha]_D^{20} = +67$ (*c* 0.25, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 28.64$ min (minor), $t_2 = 30.18$ min (major), ee = 97%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.83 (s, 1H), 7.45-7.32 (m, 1H), 7.26-7.18 (m, 3H), 7.15-7.02 (m, 3H), 7.00-6.78 (m, 7H), 6.66-6.64 (m, 1H), 6.55 (d, *J* = 7.6 Hz, 1H), 6.22 (d, *J* = 3.3 Hz, 1H), 5.69 (d, *J* = 10.0 Hz, 1H), 5.21 (d, *J* = 10.2 Hz, 1H), 3.17 (t, *J* = 10.1 Hz, 1H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 158.0, 148.2, 140.6, 140.4, 136.8, 129.3, 128.5, 127.2, 126.5, 125.7, 125.6, 125.0, 124.4, 124.3, 122.2, 122.2, 122.0, 121.5, 119.5, 118.1, 112.4, 112.2, 111.2, 60.4, 58.0, 54.0; HRMS (ESI) Calcd. For C₂₈H₂₂N₃S₂ [M+H]⁺ 464.1250, found 464.1254.


(2*R*,3*R*,4*S*)-2-(furan-2-yl)-4-(1*H*-indol-3-yl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3oa**:



White solid, M.p.: 162-163 °C; yield: 73%; $[\alpha]_D^{20} = +73$ (*c* 0.23, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 24.71$ min (major), $t_2 = 27.35$ min (minor), ee = 91%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.90 (s, 1H), 7.40-7.28 (m, 3H), 7.10-6.92 (m, 11H), 6.81-6.73 (m, 3H), 5.74 (d, *J* =


10.2 Hz, 1H), 4.82 (d, $J = 10.4$ Hz, 1H), 3.24 (t, $J = 10.3$ Hz, 1H); ^{13}C NMR (100 MHz, $\text{d}_6\text{-DMSO}$) δ ppm: 157.8, 155.9, 141.8, 140.6, 140.4, 136.8, 128.8, 128.4, 127.0, 125.6, 125.6, 125.0, 122.2, 122.2, 121.9, 121.6, 119.5, 118.2, 112.4, 112.0, 111.3, 110.3, 106.8, 58.6, 57.7, 49.8; HRMS (ESI) Calcd. For $\text{C}_{28}\text{H}_{22}\text{N}_3\text{OS}$ $[\text{M}+\text{H}]^+$ 448.1478, found 448.1478.

(2*R*,3*S*,4*S*)-8-fluoro-4-(1*H*-indol-3-yl)-2,3-diphenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3pa**:




White solid, M.p.: 136-137 °C; yield: 82%; $[\alpha]_{\text{D}}^{20} = +116$ (c 0.27, CH_2Cl_2); HPLC (Chiralpak IE, *i*-propanol/hexane = 15/85, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 7.19$ min (major), $t_2 = 9.89$ min (minor), ee = >99%; ^1H NMR (400 M, $\text{d}_6\text{-DMSO}$) δ ppm: 10.84 (s, 1H), 7.38-7.29 (m, 1H), 7.19-7.15 (m, 1H), 7.12-6.88 (m, 10H), 6.79-6.57 (m, 5H), 6.45 (d, $J = 7.2$ Hz, 1H), 5.63 (d, $J = 10.0$ Hz, 1H), 4.79 (d, $J = 10.2$ Hz, 1H), 3.08 (t, $J = 10.0$ Hz, 1H); ^{13}C NMR (100 MHz, $\text{d}_6\text{-DMSO}$) δ ppm: 159.0 (d, $J = 233.2$ Hz), 158.0, 142.8, 140.3, 140.1, 136.7, 136.6, 131.1, 129.8, 129.2, 128.4, 127.8, 127.0, 126.3, 125.6, 122.2, 122.1, 122.0, 121.8, 119.1, 111.8 (d, $J = 35.9$ Hz), 108.1 (d, $J = 24.2$ Hz), 98.5, 98.2, 63.8, 57.7, 53.6; ^{19}F NMR (376 MHz, $\text{d}_6\text{-DMSO}$) δ ppm: -122.4; HRMS (ESI) Calcd. For $\text{C}_{30}\text{H}_{23}\text{FN}_3\text{S}$ $[\text{M}+\text{H}]^+$ 476.1591, found 476.1593.

(2*R*,3*S*,4*S*)-8-chloro-4-(1*H*-indol-3-yl)-2,3-diphenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3qa**:




White solid, M.p.: 195-196 °C; yield: 82%; $[\alpha]_{\text{D}}^{20} = +84$ (c 0.25, CH_2Cl_2); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 20.66$ min (major), $t_2 = 23.83$ min (minor), ee = 98%; ^1H NMR (400 M, $\text{d}_6\text{-DMSO}$) δ ppm: 10.87 (s, 1H), 7.70-7.53 (m, 1H), 7.37-7.20 (m, 2H), 7.10-6.90 (m, 11H), 6.84-6.82 (m, 3H), 6.51 (d, $J = 8.2$ Hz, 1H), 5.70 (d, $J = 10.1$ Hz, 1H), 4.85 (d, $J = 10.4$ Hz, 1H), 3.20 (t, $J = 10.2$ Hz, 1H); ^{13}C NMR (100 MHz, $\text{d}_6\text{-DMSO}$) δ ppm: 158.0, 142.8, 140.3, 140.1, 137.1, 131.2, 129.9, 129.2, 128.5, 127.9, 127.1, 126.8, 126.4, 125.6, 123.9, 122.3, 122.2, 122.0, 119.9, 119.5, 112.0, 112.0, 111.8, 63.9, 57.5, 53.7; HRMS (ESI) Calcd. For $\text{C}_{30}\text{H}_{23}\text{ClN}_3\text{S}$ $[\text{M}+\text{H}]^+$ 492.1296, found 492.1299.

(2*R*,3*S*,4*S*)-8-bromo-4-(1*H*-indol-3-yl)-2,3-diphenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3ra**:




White solid, M.p.: 172-173 °C; yield: 83%; $[\alpha]_D^{20} = +49$ (*c* 0.32, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/92, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 22.24$ min (major), $t_2 = 28.70$ min (minor), ee = 98%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.87 (s, 1H), 7.70-7.60 (m, 1H), 7.35-7.18 (m, 2H), 7.08-6.90 (m, 12H), 6.82 (s, 2H), 6.46 (d, *J* = 9.2 Hz, 1H), 5.70 (d, *J* = 10.1 Hz, 1H), 4.85 (d, *J* = 10.4 Hz, 1H), 3.20 (t, *J* = 10.2 Hz, 1H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 157.9, 140.5, 140.4, 140.1, 140.1, 136.8, 129.8, 129.7, 129.2, 128.4, 126.9, 125.8, 125.5, 125.0, 122.2, 122.2, 121.8, 121.5, 119.5, 118.2, 114.7, 114.5, 112.4, 112.1, 111.4, 63.9, 57.9, 53.8; HRMS (ESI) Calcd. For C₃₀H₂₃BrN₃S [M+H]⁺ 536.0791, found 536.0795.

(2*R*,3*S*,4*S*)-4-(1*H*-indol-3-yl)-8-methyl-2,3-diphenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3sa**:



White solid, M.p.: 158-159 °C; yield: 72%; $[\alpha]_D^{20} = +104$ (*c* 0.25, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 26.40$ min (minor), $t_2 = 29.47$ min (major), ee = 98%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.81 (s, 1H), 7.32-7.23 (m, 3H), 7.10-6.97 (m, 9H), 6.94-6.81 (m, 4H), 6.59 (d, *J* = 7.6 Hz, 1H), 6.45 (d, *J* = 8.2 Hz, 1H), 5.66 (d, *J* = 10.1 Hz, 1H), 4.82 (d, *J* = 10.3 Hz, 1H), 3.21 (t, *J* = 10.2 Hz, 1H), 2.13 (s, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 158.0, 143.8, 140.6, 138.4, 136.8, 131.0, 129.2, 128.3, 128.1, 127.9, 126.8, 126.7, 126.1, 125.8, 125.0, 122.4, 122.2, 121.5, 119.5, 118.2, 112.4, 111.9, 111.5, 64.6, 58.1, 53.6, 20.8; HRMS (ESI) Calcd. For C₃₁H₂₆N₃S [M+H]⁺ 472.1842, found 472.1845.


(2*R*,3*S*,4*S*)-8-ethyl-4-(1*H*-indol-3-yl)-2,3-diphenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3ta**:



White solid, M.p.: 182-183 °C; yield: 80%; $[\alpha]_D^{20} = +121$ (*c* 0.32, CH₂Cl₂); HPLC (Chiralpak IE, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 13.94$ min (minor), $t_2 = 15.93$ min (major), ee = >99%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.81 (s, 1H), 7.32-7.21 (m, 2H), 7.09-6.97 (m, 10H), 6.94-6.80 (m, 4H), 6.45-6.34 (m,


2H), 5.63 (d, $J = 10.0$ Hz, 1H), 4.80 (d, $J = 10.4$ Hz, 1H), 3.86-3.81 (m, 2H), 3.20 (t, $J = 10.2$ Hz, 1H), 1.21 (t, $J = 7.0$ Hz, 3H); ^{13}C NMR (100 MHz, d_6 -DMSO) δ ppm: 158.3, 154.0, 143.8, 140.5, 136.8, 134.4, 129.2, 128.3, 128.1, 127.9, 126.8, 126.7, 125.8, 125.0, 123.4, 121.5, 119.5, 118.3, 112.6, 112.4, 111.9, 111.5, 108.5, 64.6, 63.8, 58.1, 53.6, 15.1; HRMS (ESI) Calcd. For $\text{C}_{32}\text{H}_{28}\text{N}_3\text{S}$ $[\text{M}+\text{H}]^+$ 486.1998, found 486.1997.

(2*R*,3*S*,4*S*)-4-(1*H*-indol-3-yl)-8-methoxy-2,3-diphenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3ua**:




White solid, M.p.: 155-156 °C; yield: 72%; $[\alpha]_D^{20} = +115$ (c 0.22, CH_2Cl_2); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 31.99$ min (minor), $t_2 = 34.79$ min (major), ee = 99%; ^1H NMR (400 M, d_6 -DMSO) δ ppm: 10.80 (s, 1H), 7.33-7.29 (m, 1H), 7.26-7.22 (m, 1H), 7.12-6.99 (m, 10H), 6.97-6.89 (m, 2H), 6.81 (d, $J = 6.0$ Hz, 2H), 6.47-6.37 (m, 2H), 5.64 (d, $J = 10.0$ Hz, 1H), 4.81 (d, $J = 10.4$ Hz, 1H), 3.60 (s, 3H), 3.19 (t, $J = 10.2$ Hz, 1H); ^{13}C NMR (100 MHz, d_6 -DMSO) δ ppm: 158.0, 154.7, 143.9, 140.6, 136.8, 134.6, 129.2, 128.3, 128.1, 127.9, 126.8, 126.7, 125.8, 125.1, 123.4, 121.5, 119.5, 118.5, 113.3, 112.5, 112.4, 111.6, 111.3, 108.1, 106.0, 64.7, 58.1, 55.8, 53.6; HRMS (ESI) Calcd. For $\text{C}_{31}\text{H}_{26}\text{N}_3\text{OS}$ $[\text{M}+\text{H}]^+$ 488.1791, found 488.1796.

(2*R*,3*S*,4*S*)-7-chloro-4-(1*H*-indol-3-yl)-2,3-diphenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3va**:




White solid, M.p.: 178-179 °C; yield: 80%; $[\alpha]_D^{20} = +87$ (c 0.22, CH_2Cl_2); HPLC (Chiralpak IE, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 4.13$ min (major), $t_2 = 4.64$ min (minor), ee = 98%; ^1H NMR (400 M, d_6 -DMSO) δ ppm: 10.88 (s, 1H), 7.66-7.54 (m, 1H), 7.35-7.21 (m, 2H), 7.10-6.99 (m, 9H), 6.96-6.83 (m, 5H), 6.51 (d, $J = 8.2$ Hz, 1H), 5.70 (d, $J = 10.1$ Hz, 1H), 4.85 (d, $J = 10.4$ Hz, 1H), 3.21 (t, $J = 10.3$ Hz, 1H); ^{13}C NMR (100 MHz, d_6 -DMSO) δ ppm: 158.1, 143.0, 142.5, 140.3, 136.7, 131.6, 131.3, 130.4, 129.9, 128.5, 128.0, 125.8, 125.5, 124.9, 122.2, 122.1, 121.9, 121.7, 121.6, 119.6, 118.1, 112.4, 112.1, 111.0, 63.7, 57.5, 53.3; HRMS (ESI) Calcd. For $\text{C}_{30}\text{H}_{23}\text{ClN}_3\text{S}$ $[\text{M}+\text{H}]^+$ 492.1296, found 492.1301.

(2*R*,3*S*,4*S*)-7-bromo-4-(1*H*-indol-3-yl)-2,3-diphenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3wa**:




White solid, M.p.: 180-181 °C; yield: 72%; $[\alpha]_D^{20} = +68$ (*c* 0.22, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 9.13$ min (minor), $t_2 = 9.82$ min (major), ee = >99%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.86 (s, 1H), 7.44-7.42 (m, 1H), 7.33-7.26 (m, 3H), 7.12-6.88 (m, 9H), 6.85-6.77 (m, 2H), 6.53 (d, *J* = 7.6 Hz, 1H), 6.13-6.11 (m, 1H), 5.92 (d, *J* = 3.0 Hz, 1H), 5.00 (d, *J* = 10.2 Hz, 1H), 3.51 (t, *J* = 10.0 Hz, 1H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 157.9, 142.6, 140.1, 139.9, 135.0, 131.0, 129.8, 129.2, 128.4, 127.8, 127.2, 127.0, 126.1, 125.5, 123.9, 122.2, 122.1, 121.9, 121.5, 117.3, 113.8, 111.9, 111.4, 63.8, 57.3, 53.7; HRMS (ESI) Calcd. For C₃₀H₂₃BrN₃S [M+H]⁺ 536.0791, found 536.0793.

(2*R*,3*S*,4*S*)-6-fluoro-4-(1*H*-indol-3-yl)-2,3-diphenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3xa**:



White solid, M.p.: 145-146 °C; yield: 62%; $[\alpha]_D^{20} = +45$ (*c* 0.12, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 15/85, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 10.12$ (major), $t_2 = 13.35$ min (minor), ee = 71%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.82 (s, 1H), 7.50-7.23 (m, 1H), 7.17-7.08 (m, 1H), 7.04-6.87 (m, 9H), 6.78-6.53 (m, 6H), 6.44 (d, *J* = 7.2 Hz, 1H), 5.62 (d, *J* = 10.0 Hz, 1H), 4.78 (d, *J* = 10.2 Hz, 1H), 3.07 (t, *J* = 10.0 Hz, 1H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 158.9 (d, *J* = 233.1 Hz), 157.9, 142.6, 140.2, 140.0, 136.6, 136.5, 131.0, 129.7, 129.0, 128.3, 127.7, 126.9, 126.2, 125.5, 122.1, 122.0, 121.8, 121.7, 119.0, 118.9, 111.7 (d, *J* = 35.9 Hz), 107.9 (d, *J* = 24.1 Hz), 98.4, 98.1, 63.7, 57.6, 53.5; ¹⁹F NMR (376 MHz, d₆-DMSO) δ ppm: -122.5; HRMS (ESI) Calcd. For C₃₀H₂₃FN₃S [M+H]⁺ 476.1591, found 476.1595.


(2*R*,3*S*,4*S*)-2,3-bis(4-chlorophenyl)-4-(1*H*-indol-3-yl)-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3cb**:



White solid, M.p.: 168-169 °C; yield: 78%; $[\alpha]_D^{20} = +80$ (*c* 0.23, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 15.29$ min (minor), $t_2 = 17.06$ min (major), ee = >99%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.88 (s, 1H), 7.47-7.42 (m, 1H), 7.36-7.21 (m, 2H), 7.17-6.98 (m, 8H), 6.93-6.77 (m,


5H), 6.54 (d, $J = 7.3$ Hz, 1H), 5.69 (d, $J = 10.1$ Hz, 1H), 4.87 (d, $J = 10.4$ Hz, 1H), 3.21 (t, $J = 10.2$ Hz, 1H); ^{13}C NMR (100 MHz, d_6 -DMSO) δ ppm: 158.2, 142.7, 140.4, 139.3, 136.8, 131.5, 131.3, 131.0, 129.9, 128.4, 128.0, 125.8, 125.6, 124.9, 122.2, 121.9, 121.6, 119.6, 118.1, 112.5, 112.1, 111.1, 63.8, 57.8, 53.1; HRMS (ESI) Calcd. For $\text{C}_{30}\text{H}_{22}\text{Cl}_2\text{N}_3\text{S}$ $[\text{M}+\text{H}]^+$ 526.0906, found 526.0909.

(2*R*,3*S*,4*S*)-3-(4-bromophenyl)-2-(4-chlorophenyl)-4-(1*H*-indol-3-yl)-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3cc**:




White solid, M.p.: 195-196 °C; yield: 74%; $[\alpha]^{20}_{\text{D}} = +157$ (c 0.22, CH_2Cl_2); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 16.88$ min (minor), $t_2 = 18.81$ min (major), ee = >99%; ^1H NMR (400 M, d_6 -DMSO) δ ppm: 10.91 (s, 1H), 7.48-7.46 (m, 1H), 7.34-7.29 (m, 4H), 7.27-7.12 (m, 2H), 7.10-7.01 (m, 4H), 6.96-6.81 (m, 5H), 6.57 (d, $J = 7.2$ Hz, 1H), 5.72 (d, $J = 10.1$ Hz, 1H), 4.91 (d, $J = 10.3$ Hz, 1H), 3.23 (t, $J = 10.2$ Hz, 1H); ^{13}C NMR (100 MHz, d_6 -DMSO) δ ppm: 158.1, 142.7, 140.4, 139.8, 136.8, 131.4, 131.3, 129.9, 128.1, 125.9, 125.6, 122.2, 121.9, 121.6, 120.1, 119.6, 118.1, 112.5, 112.1, 111.1, 63.7, 57.8, 53.1; HRMS (ESI) Calcd. For $\text{C}_{30}\text{H}_{22}\text{BrClN}_3\text{S}$ $[\text{M}+\text{H}]^+$ 570.0401, found 570.0402.

(2*R*,3*S*,4*S*)-2-(4-chlorophenyl)-4-(1*H*-indol-3-yl)-3-(*p*-tolyl)-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3cd**:




White solid, M.p.: 146-147 °C; yield: 64%; $[\alpha]^{20}_{\text{D}} = +107$ (c 0.24, CH_2Cl_2); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 15.02$ min (minor), $t_2 = 20.43$ min (major), ee = 99%; ^1H NMR (400 M, d_6 -DMSO) δ ppm: 10.86 (s, 1H), 7.48-7.46 (m, 1H), 7.39-7.23 (m, 2H), 7.19-7.00 (m, 6H), 6.96-6.76 (m, 7H), 6.61 (d, $J = 7.3$ Hz, 1H), 5.69 (d, $J = 10.0$ Hz, 1H), 4.87 (d, $J = 10.3$ Hz, 1H), 3.21 (t, $J = 10.1$ Hz, 1H), 2.18 (s, 3H); ^{13}C NMR (100 MHz, d_6 -DMSO) δ ppm: 158.1, 143.0, 140.5, 137.2, 136.8, 135.8, 131.1, 129.9, 129.1, 129.0, 127.9, 125.9, 125.6, 124.9, 122.2, 122.2, 121.9, 121.5, 119.5, 118.2, 112.4, 112.1, 111.3, 63.9, 58.1, 52.9, 21.1; HRMS (ESI) Calcd. For $\text{C}_{31}\text{H}_{25}\text{ClN}_3\text{S}$ $[\text{M}+\text{H}]^+$ 506.1452, found 506.1450.

(2*R*,3*S*,4*S*)-3-(4-(*tert*-butyl)phenyl)-2-(4-chlorophenyl)-4-(1*H*-indol-3-yl)-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3ce**:




White solid, M.p.: 189-190 °C; yield: 75%; $[\alpha]_D^{20} = -18$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 10.68$ min (minor), $t_2 = 13.27$ min (major), ee = >99%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.83 (s, 1H), 7.46-7.44 (m, 1H), 7.28-7.21 (m, 2H), 7.11-6.96 (m, 7H), 6.93-6.81 (m, 6H), 6.58 (d, *J* = 7.3 Hz, 1H), 5.68 (d, *J* = 9.4 Hz, 1H), 4.84 (d, *J* = 9.7 Hz, 1H), 3.23 (t, *J* = 9.6 Hz, 1H), 1.17 (s, 9H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 158.4, 149.2, 142.8, 140.4, 137.3, 136.8, 131.1, 129.8, 128.8, 127.8, 125.7, 125.2, 124.9, 122.2, 122.0, 121.5, 119.5, 118.2, 112.3, 112.1, 111.5, 63.7, 57.8, 52.6, 34.5, 31.5; HRMS (ESI) Calcd. For C₃₄H₃₁ClN₃S [M+H]⁺ 548.1922, found 548.1917.

(2*R*,3*S*,4*S*)-2-(4-chlorophenyl)-4-(1*H*-indol-3-yl)-3-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3cf**:



White solid, M.p.: 168-169 °C; yield: 74%; $[\alpha]_D^{20} = +117$ (*c* 0.25, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 11.75$ min (minor), $t_2 = 17.72$ min (major), ee = >99%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.86 (s, 1H), 7.42-7.36 (m, 3H), 7.32-7.22 (m, 2H), 7.12-6.97 (m, 8H), 6.91-6.76 (m, 3H), 6.54 (d, *J* = 7.2 Hz, 1H), 5.74 (d, *J* = 10.1 Hz, 1H), 4.87 (d, *J* = 10.3 Hz, 1H), 3.31 (t, *J* = 10.2 Hz, 1H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 158.7, 145.0, 142.2, 140.2, 136.8, 131.4, 130.1, 129.8, 128.1, 127.6 (q, *J* = 31.7 Hz), 126.0, 125.8 (q, *J* = 15.4 Hz), 125.2, 124.8, 123.2, 122.2, 120.9 (q, *J* = 246.7 Hz), 118.1, 112.5, 112.2, 110.9, 63.6, 57.7, 53.5; ¹⁹F NMR (376 MHz, d₆-DMSO) δ ppm: -60.8; HRMS (ESI) Calcd. For C₃₁H₂₂F₃N₃S [M+H]⁺ 560.1170, found 560.1173.


(2*R*,3*S*,4*S*)-3-(3-bromophenyl)-2-(4-chlorophenyl)-4-(1*H*-indol-3-yl)-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3cg**:



White solid, M.p.: 162-163 °C; yield: 81%; $[\alpha]_D^{20} = +85$ (*c* 0.32, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 12.83$ min (minor), $t_2 = 20.45$ min (major), ee = 99%; ¹H NMR (400 M, d₆-DMSO) δ ppm:


10.93 (s, 1H), 7.51-7.41 (m, 1H), 7.39-7.20 (m, 6H), 7.12-7.09 (m, 3H), 7.05-6.93 (m, 3H), 6.90-6.81 (m, 3H), 6.59 (d, $J = 6.9$ Hz, 1H), 5.78 (d, $J = 10.1$ Hz, 1H), 4.91 (d, $J = 10.2$ Hz, 1H), 3.25 (t, $J = 10.2$ Hz, 1H); ^{13}C NMR (100 MHz, d_6 -DMSO) δ ppm: 158.2, 143.1, 142.6, 140.4, 136.8, 131.7, 131.3, 130.5, 129.9, 129.9, 128.5, 128.0, 125.8, 125.6, 125.0, 122.2, 122.2, 122.0, 121.8, 121.6, 119.6, 118.1, 112.5, 112.1, 111.0, 63.8, 57.5, 53.4; HRMS (ESI) Calcd. For $\text{C}_{30}\text{H}_{22}\text{BrClN}_3\text{S}$ $[\text{M}+\text{H}]^+$ 570.0401, found 570.0401.

(2*R*,3*S*,4*S*)-2-(4-chlorophenyl)-4-(1*H*-indol-3-yl)-3-(*m*-tolyl)-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3ch**:




White solid, M.p.: 137-138 °C; yield: 77%; $[\alpha]_D^{20} = +127$ (c 0.26, CH_2Cl_2); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 23.49$ min (minor), $t_2 = 28.43$ min (major), ee = 98%; ^1H NMR (400 M, d_6 -DMSO) δ ppm: 10.84 (s, 1H), 7.45-7.43 (m, 1H), 7.33-7.25 (m, 2H), 7.14-7.03 (m, 2H), 7.01-6.97 (m, 4H), 6.94-6.89 (m, 2H), 6.86-6.73 (m, 4H), 6.59 (d, $J = 7.0$ Hz, 1H), 5.70 (d, $J = 9.9$ Hz, 1H), 4.82 (d, $J = 10.1$ Hz, 1H), 3.17 (t, $J = 10.0$ Hz, 1H), 2.10 (s, 3H); ^{13}C NMR (100 MHz, d_6 -DMSO) δ ppm: 158.2, 142.9, 140.2, 137.3, 136.8, 131.1, 129.9, 129.7, 128.3, 127.8, 127.7, 126.4, 125.8, 125.6, 125.0, 122.2, 122.2, 121.9, 121.5, 119.5, 118.2, 112.4, 112.1, 111.4, 64.0, 57.9, 53.3, 21.4; HRMS (ESI) Calcd. For $\text{C}_{31}\text{H}_{25}\text{ClN}_3\text{S}$ $[\text{M}+\text{H}]^+$ 506.1452, found 506.1452.

(2*R*,3*S*,4*S*)-2-(4-chlorophenyl)-4-(1*H*-indol-3-yl)-3-(*o*-tolyl)-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3ci**:




White solid, M.p.: 132-133 °C; yield: 64%; $[\alpha]_D^{20} = +109$ (c 0.23, CH_2Cl_2); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 22.74$ min (minor), $t_2 = 24.95$ min (major), ee = 95%; ^1H NMR (400 M, d_6 -DMSO) δ ppm: 10.87 (s, 1H), 7.77-7.68 (m, 1H), 7.62-7.43 (m, 1H), 7.41-7.21 (m, 3H), 7.17-7.05 (m, 2H), 7.03-6.81 (m, 8H), 6.64 (d, $J = 7.6$ Hz, 1H), 5.67 (d, $J = 10.2$ Hz, 1H), 4.87 (d, $J = 10.5$ Hz, 1H), 3.54 (t, $J = 10.4$ Hz, 1H), 0.96 (s, 3H); ^{13}C NMR (100 MHz, d_6 -DMSO) δ ppm: 158.2, 147.8, 140.4, 139.1, 137.4, 136.7, 131.2, 129.8, 129.6, 128.0, 127.7, 126.6, 125.5, 125.2, 122.2, 122.2, 121.9, 121.6, 119.7, 118.0, 112.4, 112.2, 111.0, 64.1, 58.4, 47.7, 18.9; HRMS (ESI) Calcd. For $\text{C}_{31}\text{H}_{25}\text{ClN}_3\text{S}$ $[\text{M}+\text{H}]^+$ 506.1452, found 506.1455.

(2*R*,3*S*,4*S*)-4-(4-chloro-1*H*-indol-3-yl)-2-(4-chlorophenyl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3cj**:




White solid, M.p.: 168-169 °C; yield: 75%; $[\alpha]_D^{20} = +40$ (*c* 0.12, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 12.14$ min (major), $t_2 = 16.17$ min (minor), ee = >99%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.83 (s, 1H), 7.77-7.45 (m, 1H), 7.31-7.23 (m, 2H), 7.14-6.98 (m, 8H), 6.95-6.91 (m, 3H), 6.88-6.78 (m, 2H), 6.42 (d, *J* = 8.2 Hz, 1H), 5.66 (d, *J* = 10.1 Hz, 1H), 4.81 (d, *J* = 10.4 Hz, 1H), 3.17 (t, *J* = 10.2 Hz, 1H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 157.7, 142.5, 140.0, 139.8, 134.9, 130.9, 129.7, 129.0, 128.2, 127.6, 127.1, 126.8, 126.0, 125.4, 123.7, 122.1, 121.9, 121.8, 121.3, 117.2, 113.6, 111.7, 111.3, 63.7, 57.2, 53.5; HRMS (ESI) Calcd. For C₃₀H₂₂Cl₂N₃S [M+H]⁺ 526.0906, found 526.0906.

(2*R*,3*S*,4*S*)-4-(5-chloro-1*H*-indol-3-yl)-2-(4-chlorophenyl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3ck**:



White solid, M.p.: 177-178 °C; yield: 76%; $[\alpha]_D^{20} = +97$ (*c* 0.1, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 12.51$ min (minor), $t_2 = 14.36$ min (major), ee = 98%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 11.07 (s, 1H), 7.51-7.41 (m, 1H), 7.31-7.17 (m, 2H), 7.14-7.04 (m, 8H), 6.99-6.97 (m, 1H), 6.91-6.80 (m, 4H), 6.46 (d, *J* = 6.8 Hz, 1H), 5.73 (d, *J* = 10.0 Hz, 1H), 4.87 (d, *J* = 10.2 Hz, 1H), 3.11 (t, *J* = 10.0 Hz, 1H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 158.0, 142.7, 140.2, 140.0, 135.1, 131.2, 129.9, 129.3, 128.5, 127.9, 127.3, 127.1, 126.2, 125.6, 124.0, 122.3, 122.2, 122.0, 121.6, 117.4, 113.9, 112.0, 111.5, 63.9, 57.4, 53.8; HRMS (ESI) Calcd. For C₃₀H₂₂Cl₂N₃S [M+H]⁺ 526.0906, found 526.0909.


(2*R*,3*S*,4*S*)-2-(4-chlorophenyl)-4-(5-methyl-1*H*-indol-3-yl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3cl**:



White solid, M.p.: 145-146 °C; yield: 64%; $[\alpha]_D^{20} = +175$ (*c* 0.24, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 14.79$


min (minor), $t_2 = 16.59$ min (major), ee = 99%; ^1H NMR (400 M, d_6 -DMSO) δ ppm: 10.72 (s, 1H), 7.45-7.43 (m, 1H), 7.15-7.12 (dn, 3H), 7.07-6.99 (m, 6H), 6.89-6.74 (m, 6H), 6.56 (d, $J = 7.0$ Hz, 1H), 5.67 (d, $J = 10.0$ Hz, 1H), 4.86 (d, $J = 10.2$ Hz, 1H), 3.19 (t, $J = 10.1$ Hz, 1H), 2.29 (s, 3H); ^{13}C NMR (100 MHz, d_6 -DMSO) δ ppm: 158.2, 142.9, 140.5, 140.3, 135.2, 131.2, 129.9, 129.2, 128.4, 127.9, 127.8, 127.0, 125.7, 125.5, 125.3, 123.2, 122.2, 121.9, 117.9, 112.1, 112.1, 110.9, 64.0, 58.6, 53.5, 22.0; HRMS (ESI) Calcd. For $\text{C}_{31}\text{H}_{25}\text{ClN}_3\text{S}$ $[\text{M}+\text{H}]^+$ 506.1452, found 506.1457.

(2*R*,3*S*,4*S*)-2-(4-chlorophenyl)-4-(6-fluoro-1*H*-indol-3-yl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3cm**:




White solid, M.p.: 177-178 °C; yield: 74%; $[\alpha]_D^{20} = +83$ (c 0.21, CH_2Cl_2); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 21.18$ min (minor), $t_2 = 23.53$ min (major), ee = >99%; ^1H NMR (400 M, d_6 -DMSO) δ ppm: 10.92 (s, 1H), 7.47-7.44 (m, 1H), 7.33-7.18 (m, 1H), 7.14-7.02 (m, 8H), 6.97-6.76 (m, 6H), 6.54 (d, $J = 7.2$ Hz, 1H), 5.72 (d, $J = 10.0$ Hz, 1H), 4.87 (d, $J = 10.2$ Hz, 1H), 3.17 (t, $J = 10.0$ Hz, 1H); ^{13}C NMR (100 MHz, d_6 -DMSO) δ ppm: 159.1 (d, $J = 233.3$ Hz), 158.1, 142.8, 140.4, 140.1, 136.7, 136.6, 131.2, 129.9, 129.2, 128.5, 127.9, 127.0, 126.3, 125.6, 122.3, 122.2, 122.0, 119.2, 119.1, 111.8 (d, $J = 35.8$ Hz), 108.1 (d, $J = 24.3$ Hz), 98.5, 98.3, 63.8, 57.7, 53.6; ^{19}F NMR (376 MHz, d_6 -DMSO) δ ppm: -121.83; HRMS (ESI) Calcd. For $\text{C}_{30}\text{H}_{22}\text{ClFN}_3\text{S}$ $[\text{M}+\text{H}]^+$ 510.1202, found 510.1199.

(2*R*,3*S*,4*S*)-4-(6-chloro-1*H*-indol-3-yl)-2-(4-chlorophenyl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3cn**:




White solid, M.p.: 162-163 °C; yield: 80%; $[\alpha]_D^{20} = +122$ (c 0.24, CH_2Cl_2); HPLC (Chiralpak ID, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 11.35$ min (minor), $t_2 = 12.65$ min (major), ee = 99%; ^1H NMR (400 M, d_6 -DMSO) δ ppm: 11.00 (s, 1H), 7.46-7.44 (m, 1H), 7.32-7.23 (m, 2H), 7.17-7.08 (m, 2H), 7.06-7.01 (m, 6H), 6.94-6.79 (m, 5H), 6.49 (d, $J = 6.7$ Hz, 1H), 5.72 (d, $J = 10.0$ Hz, 1H), 4.87 (d, $J = 10.2$ Hz, 1H), 3.14 (t, $J = 10.1$ Hz, 1H); ^{13}C NMR (100 MHz, d_6 -DMSO) δ ppm: 158.0, 142.8, 140.3, 140.0, 133.5, 131.2, 129.9, 129.2, 128.5, 127.9, 127.1, 125.7, 122.3, 122.2, 122.0, 121.3, 121.2, 120.7, 117.3, 116.6, 112.9, 112.0, 63.8, 57.6, 53.6; HRMS (ESI) Calcd. For $\text{C}_{30}\text{H}_{22}\text{Cl}_2\text{N}_3\text{S}$ $[\text{M}+\text{H}]^+$ 526.0906, found 526.0911.

(2*R*,3*S*,4*S*)-4-(6-bromo-1*H*-indol-3-yl)-2-(4-chlorophenyl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3co**:




White solid, M.p.: 196-197 °C; yield: 80%; $[\alpha]^{20}_D = +106$ (*c* 0.28, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 11.80$ min (minor), $t_2 = 13.31$ min (major), ee = >99%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 11.01 (s, 1H), 7.45-7.42 (m, 2H), 7.22-7.10 (m, 1H), 7.12-6.99 (m, 9H), 6.86-6.77 (m, 4H), 6.48 (d, *J* = 6.7 Hz, 1H), 5.70 (d, *J* = 10.0 Hz, 1H), 4.84 (d, *J* = 10.1 Hz, 1H), 3.14 (t, *J* = 10.0 Hz, 1H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 158.1, 142.7, 140.3, 140.0, 137.6, 131.2, 129.9, 129.2, 128.5, 127.9, 127.1, 126.7, 125.6, 124.1, 122.4, 122.2, 122.1, 119.9, 115.0, 114.5, 112.0, 111.9, 63.9, 57.6, 53.6; HRMS (ESI) Calcd. For C₃₀H₂₂BrClN₃S [M+H]⁺ 570.0401, found 570.0405.

(2*R*,3*S*,4*S*)-2-(4-chlorophenyl)-4-(6-methyl-1*H*-indol-3-yl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3cp**:




White solid, M.p.: 158-159 °C; yield: 72%; $[\alpha]^{20}_D = +154$ (*c* 0.32, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 13.24$ min (minor), $t_2 = 15.68$ min (major), ee = 98%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.79 (s, 1H), 7.42-7.12 (m, 2H), 7.09-6.96 (m, 9H), 6.93-6.67 (m, 4H), 6.58 (d, *J* = 7.6 Hz, 1H), 6.44 (d, *J* = 8.2 Hz, 1H), 5.65 (d, *J* = 10.0 Hz, 1H), 4.81 (d, *J* = 10.4 Hz, 1H), 3.20 (t, *J* = 10.2 Hz, 1H), 2.11 (s, 3H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 158.4, 142.8, 140.4, 140.1, 137.2, 131.2, 130.7, 129.8, 129.2, 128.4, 127.9, 127.0, 125.5, 125.0, 122.8, 122.2, 122.1, 122.0, 121.4, 117.9, 112.2, 63.9, 58.1, 21.7; HRMS (ESI) Calcd. For C₃₁H₂₅ClN₃S [M+H]⁺ 506.1452, found 506.1455.

(2*R*,3*S*,4*S*)-2-(4-chlorophenyl)-4-(6-methoxy-1*H*-indol-3-yl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3cq**:




White solid, M.p.: 152-153 °C; yield: 78%; $[\alpha]^{20}_D = +141$ (*c* 0.34, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 20.39$ min (minor), $t_2 = 25.82$ min (major), ee = 99%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 10.64 (s, 1H), 7.45-7.39 (m, 1H), 7.18-7.12 (m, 3H), 7.08-7.01 (m, 5H), 6.86-6.76 (m, 6H), 6.59-6.56 (m, 2H), 5.65 (d, *J* = 10.0 Hz, 1H), 4.85 (d, *J* = 10.3 Hz, 1H), 3.69 (s, 3H), 3.17 (t, *J* = 10.1 Hz, 1H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 158.1, 155.8, 142.9, 140.5, 137.6, 131.2, 129.8, 129.2, 128.4, 127.9, 127.0, 125.6, 124.4, 122.2, 122.2, 121.9, 119.3, 118.8, 112.1, 111.3, 109.7, 95.4, 64.0, 58.0, 55.4, 53.7; HRMS (ESI) Calcd. For C₃₁H₂₅ClN₃OS [M+H]⁺ 522.1401, found 522.1406.

(2*R*,3*S*,4*S*)-4-(7-chloro-1*H*-indol-3-yl)-2-(4-chlorophenyl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3cr**:



White solid, M.p.: 145-146 °C; yield: 64%; $[\alpha]^{20}_D = +120$ (*c* 0.2, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 9.36$ min (minor), $t_2 = 11.36$ min (major), ee = >99%; ¹H NMR (400 M, d₆-DMSO) δ ppm: 11.29 (s, 1H), 7.50-7.45 (m, 1H), 7.30-7.22 (m, 1H), 7.17-7.04 (m, 9H), 6.98-6.83 (m, 5H), 6.56 (d, *J* = 6.0 Hz, 1H), 5.79 (d, *J* = 10.0 Hz, 1H), 4.91 (d, *J* = 10.2 Hz, 1H), 3.20 (t, *J* = 10.0 Hz, 1H); ¹³C NMR (100 MHz, d₆-DMSO) δ ppm: 158.0, 142.8, 140.3, 140.0, 133.5, 131.2, 129.9, 129.2, 128.5, 127.9, 127.1, 125.7, 122.3, 122.2, 122.0, 121.3, 121.2, 120.7, 117.3, 116.6, 112.9, 112.0, 63.8, 57.6, 53.6; HRMS (ESI) Calcd. For C₃₀H₂₂Cl₂N₃S [M+H]⁺ 526.0906, found 526.0908.


(2*R*,3*S*,4*S*)-2-(4-chlorophenyl)-4-(7-methyl-1*H*-indol-3-yl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3cs**:



White solid, M.p.: 134-135 °C; yield: 74%; $[\alpha]^{20}_D = +174$ (*c* 0.21, CH₂Cl₂); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 27.07$


min (minor), $t_2 = 30.78$ min (major), ee = >99%; ^1H NMR (400 M, d_6 -DMSO) δ ppm: 10.82 (s, 1H), 7.45-7.42 (m, 1H), 7.19-7.11 (m, 3H), 7.08-6.96 (m, 6H), 6.85-6.78 (m, 6H), 6.59 (d, $J = 6.9$ Hz, 1H), 5.71 (d, $J = 10.0$ Hz, 1H), 4.84 (d, $J = 10.2$ Hz, 1H), 3.19 (t, $J = 10.1$ Hz, 1H), 2.34 (s, 3H); ^{13}C NMR (100 MHz, d_6 -DMSO) δ ppm: 158.2, 142.9, 140.5, 140.3, 136.4, 131.1, 129.9, 129.2, 128.5, 127.9, 127.0, 125.6, 124.6, 122.2, 122.2, 122.1, 121.9, 121.4, 119.8, 115.8, 112.1, 111.8, 64.0, 58.0, 53.6, 17.2; HRMS (ESI) Calcd. For $\text{C}_{31}\text{H}_{25}\text{ClN}_3\text{S}$ $[\text{M}+\text{H}]^+$ 506.1452, found 506.1456.

(2*R*,3*S*,4*S*)-2-(4-chlorophenyl)-4-(2-methyl-1*H*-indol-3-yl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **3ct**:



White solid, M.p.: 178-179 °C; yield: 62%; $[\alpha]_D^{20} = +123$ (c 0.24, CH_2Cl_2); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 7.58$ min (major), $t_2 = 9.25$ min (minor), ee = 96%; ^1H NMR (400 M, d_6 -DMSO) δ ppm: 10.86 (s, 1H), 7.48-7.44 (m, 1H), 7.38-7.21 (m, 2H), 7.13-6.99 (m, 4H), 6.97-6.90 (m, 5H), 6.86-6.79 (m, 4H), 6.58 (d, $J = 7.4$ Hz, 1H), 5.69 (d, $J = 10.1$ Hz, 1H), 4.83 (d, $J = 10.4$ Hz, 1H), 3.23 (t, $J = 10.2$ Hz, 1H), 2.17 (s, 3H); ^{13}C NMR (100 MHz, d_6 -DMSO) δ ppm: 157.6, 140.9, 140.7, 140.6, 136.8, 135.4, 129.3, 128.5, 128.3, 128.0, 126.8, 125.7, 125.5, 125.0, 122.3, 122.1, 121.8, 121.5, 119.5, 118.2, 112.4, 112.0, 111.5, 64.3, 58.1, 53.6, 21.1; HRMS (ESI) Calcd. For $\text{C}_{31}\text{H}_{25}\text{ClN}_3\text{S}$ $[\text{M}+\text{H}]^+$ 506.1452, found 506.1456.


(2*R*,3*S*,4*S*)-2-(4-chlorophenyl)-4-(1-methyl-1*H*-indol-3-yl)-3-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidine **4**:





White solid, M.p.: 178-179 °C; yield: 86%; $[\alpha]_D^{20} = +123$ (c 0.24, CH_2Cl_2); HPLC (Chiralpak ID, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 254$ nm), $t_1 = 13.83$ min (major), $t_2 = 17.84$ min (minor), ee = >99%; ^1H NMR (400 M, d_6 -DMSO) δ ppm: 7.46-7.42 (m, 1H), 7.34-7.26 (m, 2H), 7.15-7.02 (m, 8H), 6.97-6.79 (m, 6H), 6.55 (d, $J = 7.3$ Hz, 1H), 5.72 (d, $J = 9.4$ Hz, 1H), 4.85 (d, $J = 9.7$ Hz, 1H), 3.54 (s, 3H), 3.23 (t, $J = 9.6$ Hz, 1H); ^{13}C NMR (100 MHz, d_6 -DMSO) δ ppm: 158.2, 155.9, 143.0, 140.6, 140.4, 137.7, 131.3, 130.0, 129.3, 128.5, 128.0, 127.1, 125.7, 124.5, 122.3, 122.2, 122.0, 119.4, 118.8, 112.2, 111.4, 109.8, 95.5, 64.1, 58.1, 55.5, 53.8; HRMS (ESI) Calcd. For $\text{C}_{31}\text{H}_{25}\text{ClN}_3\text{S}$ $[\text{M}+\text{H}]^+$ 506.1452, found 506.1453.

5. Crystallographic data collection for compound 3oa.

Bond precision: C-C = 0.0120 Å Wavelength=1.54184
Cell: a=8.7321(2) b=15.7556(4) c=9.1821(2)
alpha=90 beta=100.916(2) gamma=90
Temperature: 200 K
Calculated Reported
Volume 1240.41(5) 1240.41(5)
Space group P 21 P 1 21 1
Hall group P 2yb P 2yb
Moiety formula C₂₈ H₂₁ N₃ O S, C H₂ Cl₂ C₂₈ H₂₁ N₃ O S, C H₂ Cl₂
Sum formula C₂₉ H₂₃ Cl₂ N₃ O S C₂₉ H₂₃ Cl₂ N₃ O S
Mr 532.46 532.46
D_x, g cm⁻³ 1.426 1.426
Z 2 2
Mu (mm⁻¹) 3.369 3.369
F₀₀₀ 552.0 552.0
F₀₀₀' 555.40
h,k,l_{max} 10,18,11 10,18,10
N_{ref} 4544[2362] 4544
T_{min}, T_{max} 0.868,0.904 0.868,0.904
T_{min}' 0.859
Correction method= # Reported T Limits: T_{min}=0.868 T_{max}=0.904
AbsCorr = MULTI-SCAN
Data completeness= 1.92/1.00 Theta(max)= 68.217
R(reflections)= 0.0938(3103)
wR₂(reflections)=
0.2506(3364)
S = 1.172 N_{par}= 325
The following ALERTS were generated. Each ALERT has the format
test-name_ALERT_alert-type_alert-level.
Click on the hyperlinks for more details of the test.





6. HPLC spectra of compounds.



++ ± ± 0

Show





No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width	Peak Type
1	18.89	988777	21106	49.63%	2.404	BB
2	21.43	1003623	20003	50.37%	2.692	BB
total		1,992,400	41,109	100.00%		











++ ± ± 0



Show

No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width	Peak Type
1	18.75	11466427	253719	98.11%	3.318	BB
2	21.58	220741	6639	1.89%	0.93	BB
total		11,687,168	260,358	100.00%		























No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width	Peak Type
1	11.89	2531617	82478	48.91%	1.248 BV	
2	13.03	2644687	90961	51.09%	1.581 VB	
Total		5,176,304	173,439	100.00%		











No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width	Peak Type
1	12.00	83344	3736	1.10%	0.618 BB	
2	13.02	7489617	273499	98.90%	2.174 BB	
Total		7,572,961	277,235	100.00%		



























































No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width	Peak Type
1	7.21	3012975	137409	49.75%	1.584	BB
2	9.84	3042911	109792	50.25%	2.291	BB
Total		6,055,886	247,201	100.00%		











No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width	Peak Type
1	7.19	6454722	296388	99.55%	1.786	BB
2	9.89	29342	2146	0.45%	0.386	BB
Total		6,484,064	298,534	100.00%		





























No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width	Peak Type
1	4.12	864694	100986	49.85%	0.557 BV	
2	4.66	869927	90774	50.15%	0.758 VB	











No.	Retention Time	Peak Area	Peak Height	Peak Area(%)	Peak Width	Peak Type
1	4.13	4022330	500626	99.08%	0.633 BV	
2	4.64	37330	2897	0.92%	0.494 VB	
nl		4 059 660	503 523	100.00%		















































































































No.	Retention Time	PeakArea	Peak Height	PeakArea(%)	Peak Width	Peak Type
1	8.40	1069875	62196	49.76%	1.578	BB
2	10.26	1080269	44529	50.24%	1.833	BB
Total		2,150,144	106,725	100.00%		



No.	Retention Time	PeakArea	Peak Height	PeakArea(%)	Peak Width	Peak Type
1	7.58	439079	26264	97.90%	1.926	BB
2	9.25	9413	445	2.10%	0.917	BB
Total		448,492	26,709	100.00%		




No.	Retention Time	PeakArea	Peak Height	PeakArea(%)	Peak Width	Peak Type
1	13.84	1998399	33016	49.50%	4.15 BV	
2	17.80	2038543	27486	50.50%	5.547 VB	
Total		4,036,942	60,502	100.00%		




No.	Retention Time	PeakArea	Peak Height	PeakArea(%)	Peak Width	Peak Type
1	13.83	4884486	82280	99.67%	4.171 BB	
2	17.84	16388	676	0.33%	0.746 BB	
Total		4,900,874	82,956	100.00%		

7. NMR Spectra of compounds.


^1H NMR spectrum of compound **3aa** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3aa** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




¹H NMR spectrum of compound **3ba** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3ba** ((CD₃)₂SO, 100 MHz)




^{19}F NMR spectrum of compound **3ba** ($(\text{CD}_3)_2\text{SO}$, 376 MHz)




¹H NMR spectrum of compound **3ca** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3ca** ((CD₃)₂SO, 100 MHz)




¹H NMR spectrum of compound **3da** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3da** ((CD₃)₂SO, 100 MHz)




¹H NMR spectrum of compound **3ea** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3ea** ((CD₃)₂SO, 100 MHz)




¹H NMR spectrum of compound **3fa** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3fa** ((CD₃)₂SO, 100 MHz)




^1H NMR spectrum of compound **3ga** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3ga** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




¹H NMR spectrum of compound **3ha** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3ha** ((CD₃)₂SO, 100 MHz)




¹H NMR spectrum of compound **3ia** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3ia** ((CD₃)₂SO, 100 MHz)




^1H NMR spectrum of compound **3ja** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3ja** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




^1H NMR spectrum of compound **3ka** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3ka** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




¹H NMR spectrum of compound **3la** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3la** ((CD₃)₂SO, 100 MHz)




¹H NMR spectrum of compound **3ma** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3ma** ((CD₃)₂SO, 100 MHz)




^1H NMR spectrum of compound **3na** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3na** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




^1H NMR spectrum of compound **3oa** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3oa** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




¹H NMR spectrum of compound **3pa** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3pa** ((CD₃)₂SO, 100 MHz)




^{19}F NMR spectrum of compound **3pa** ($(\text{CD}_3)_2\text{SO}$, 376 MHz)




¹H NMR spectrum of compound **3qa** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3qa** ((CD₃)₂SO, 100 MHz)




^1H NMR spectrum of compound **3ra** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3ra** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




^1H NMR spectrum of compound **3sa** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3sa** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




^1H NMR spectrum of compound **3ta** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3ta** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




^1H NMR spectrum of compound **3ua** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3ua** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




¹H NMR spectrum of compound **3va** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3va** ((CD₃)₂SO, 100 MHz)




¹H NMR spectrum of compound **3wa** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3wa** ((CD₃)₂SO, 100 MHz)




^1H NMR spectrum of compound **3xa** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3xa** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




^{19}F NMR spectrum of compound **3xa** ($(\text{CD}_3)_2\text{SO}$, 376 MHz)




^1H NMR spectrum of compound **3cb** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3cb** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




^1H NMR spectrum of compound **3cc** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3cc** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




¹H NMR spectrum of compound **3cd** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3cd** ((CD₃)₂SO, 100 MHz)




¹H NMR spectrum of compound **3ce** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3ce** ((CD₃)₂SO, 100 MHz)




^1H NMR spectrum of compound **3cf** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3cf** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




^{19}F NMR spectrum of compound **3cf** ($(\text{CD}_3)_2\text{SO}$, 376 MHz)




^1H NMR spectrum of compound **3cg** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3cg** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




¹H NMR spectrum of compound **3ch** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3ch** ((CD₃)₂SO, 100 MHz)




^1H NMR spectrum of compound **3ci** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3ci** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




^1H NMR spectrum of compound **3cj** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3cj** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




^1H NMR spectrum of compound **3ck** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3ck** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




^1H NMR spectrum of compound **3cl** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3cl** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




¹H NMR spectrum of compound **3cm** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3cm** ((CD₃)₂SO, 100 MHz)




^{19}F NMR spectrum of compound **3cm** ($(\text{CD}_3)_2\text{SO}$, 376 MHz)




¹H NMR spectrum of compound **3cn** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3cn** ((CD₃)₂SO, 100 MHz)




^1H NMR spectrum of compound **3co** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3co** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




^1H NMR spectrum of compound **3cp** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3cp** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




¹H NMR spectrum of compound **3cq** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3cq** ((CD₃)₂SO, 100 MHz)




¹H NMR spectrum of compound **3cr** ((CD₃)₂SO, 400 MHz)




¹³C NMR spectrum of compound **3cr** ((CD₃)₂SO, 100 MHz)




^1H NMR spectrum of compound **3cs** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)




^{13}C NMR spectrum of compound **3cs** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)




^1H NMR spectrum of compound **3ct** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)



^{13}C NMR spectrum of compound **3ct** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)



^1H NMR spectrum of compound **4** ($(\text{CD}_3)_2\text{SO}$, 400 MHz)



^{13}C NMR spectrum of compound **4** ($(\text{CD}_3)_2\text{SO}$, 100 MHz)

